drugset
drugset / Trial / NCT05264506

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

NCT05264506 ↗

Phase 3 Terminated 3055 enrolled Organon and Co IQVIA Pty Ltd · collab
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).

Timeline

Start
2022-02-17
Primary completion
2024-01-12
Completion
2024-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 1.5 mg Oral
Subject Nomegestrol Acetate Small molecule 2.5 mg Oral

Indications

No indication recorded.